Crizotinib

Crizotinib is a newly initially approved drug by the FDA. Crizotinib is an oral tyrosine kinase inhibitor which is used for the treatment of patient with locally advanced or metastatic non small cell lung cancer that has to be positive as an anaplastic lymphoma kinase (ALK) which is a FDA approved test. The treatment with crizotinib is response rate based. Crizotinib has demonstratedconcentration dependent inhibition of ALK & c-met phosphorylation in cell based assay using tumor cell line and demonstrated antitumor activity.

Brands

Adult Dose

Neonatal

Paedriatic

Characteristics

It belongs to Tyrosine kinase inhibitor pharmacological group on the basis of mechanism of action. The Molecular Weight of Crizotinib is 450.34. Its pKa is 9.4.

Contraindications

Crizotinib

Effects

The symptomatic adverse reactions produced by Crizotinib are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Diarrhea, Constipation, Yision disorder, Yomiting.

Indications

Crizotinib is primarily indicated in conditions like Non small cell lung cancer.

Interactions

No data regarding the interactions of Crizotinib was found.

Interfrence

Risks

If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Storage

Caps Store at room temperature, Between 20°C-25°C.

Warnings

Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.